Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood

Phase 2

Terminated

Conditions: Leukemia
Lymphoma, Low-Grade
Lymphoma, Non-Hodgkin's
Multiple Myeloma
Myelodysplastic Syndromes

First Posted Date: 2005-09-02

Last Posted Date: 2007-04-23

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 30

Registration Number: NCT00143884

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

Phase 2

Completed

Conditions: Multiple Myeloma
Lymphocytic Leukemia, Chronic
Lymphoma, Low-Grade

First Posted Date: 2005-09-02

Last Posted Date: 2017-03-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 54

Registration Number: NCT00143845

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

Phase 2

Completed

Conditions: Wilms Tumor
Fibrosarcoma
Carcinoma, Round Cell
Nasopharyngeal Cancer
Brain Tumor, Recurrent

First Posted Date: 2005-09-01

Last Posted Date: 2014-06-20

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 25

Registration Number: NCT00141765

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin's

First Posted Date: 2005-09-01

Last Posted Date: 2008-01-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 30

Registration Number: NCT00141700

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Phase 2

Completed

Conditions: Lung Injury, Acute
Respiratory Distress Syndrome, Adult
Bronchiolitis Obliterans

Interventions: Drug: Etanercept

First Posted Date: 2005-09-01

Last Posted Date: 2015-12-03

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 34

Registration Number: NCT00141726

Locations: 🇺🇸
The University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2

Completed

Conditions: Graft-Versus-Host Disease

Interventions: Drug: Etanercept

First Posted Date: 2005-09-01

Last Posted Date: 2017-01-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 100

Registration Number: NCT00141739

Locations: 🇺🇸
Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

Phase 2

Completed

Conditions: Graft-Versus-Host Disease

Interventions: Drug: Etanercept

First Posted Date: 2005-09-01

Last Posted Date: 2013-03-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT00141713

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2005-08-26

Last Posted Date: 2015-01-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 68

Registration Number: NCT00136175

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Iodine I 131 Tositumomab

First Posted Date: 2005-08-25

Last Posted Date: 2025-04-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 16

Registration Number: NCT00135200

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Not Applicable

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-08-25

Last Posted Date: 2012-02-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 30

Registration Number: NCT00135187

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy